Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program of TWIN for the Treatment of Acne Vulgaris
First subject dosed in pivotal Phase III program evaluating TWIN in subjects with moderate-to-severe acne vulgaris Two Phase III trials […]
Vogogo Announces Voting Results
TORONTO, Dec. 17, 2018 (GLOBE NEWSWIRE) — Vogogo Inc. (“Vogogo” or the “Company”) (CSE:VGO) today announces the voting results from […]
LiteLink Launches Alpha Release for 1SHIFT Logistics Platform
VANCOUVER, British Columbia, Dec. 17, 2018 (GLOBE NEWSWIRE) — LiteLink Technologies Inc. (“LiteLink”), a key player in Technology and Artificial […]
ALIMENTATION COUCHE-TARD AND CROSSAMERICA ANNOUNCE AGREEMENT FOR SERIES OF ASSET EXCHANGES
-Alimentation Couche-Tard has agreed to sell to CrossAmerica 192 U.S. company-operated convenience and fuel retail stores (the “Circle K stores”) […]
Mechel Expands Long-Term Coal Supply Agreement With Japan’s Itochu Corporation
SINGAPORE, Dec. 17, 2018 (GLOBE NEWSWIRE) — Mechel PAO (MOEX: MTLR; NYSE: MTL), a leading Russian mining and metals company, […]
Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease
CARMIEL, Israel, Dec. 17, 2018 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and […]
U.S. Well Services Expands Liquidity Through New Credit Facility, Provides Business Update
HOUSTON, Dec. 17, 2018 (GLOBE NEWSWIRE) — U.S. Well Services, Inc. (NASDAQ: USWS) (“USWS” or the “company”) today announced an […]
Plug Power Named to Food Logistics’ 2018 FL100+ Top Software and Technology Providers
For the 5th Year, Plug Power is Recognized for its Cutting-Edge Technology LATHAM, N. Y., Dec. 17, 2018 (GLOBE NEWSWIRE) […]
Surface Oncology Promotes Jessica Fees to Senior Vice President, Finance and Business Operations
CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that […]
Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
DM is a rare systemic autoimmune disease that affects ~80,000 individuals in the U.S., EU and Japan and has a […]
